Following spinal cord injury (SCI), chronic pain is a common secondary complication with neuropathic pain (NP) cited as one of the most distressing and debilitating conditions leading to poor quality of life, depression and sleep disturbances. Neuropathic pain presenting at or below the level of injury is largely refractory to current pharmacological and physical treatments. No consensus on the prevalence of NP post SCI currently exists, hence this systematic review was undertaken. The review comprised three phases: a methodological assessment of databases [PubMed, Embase, Web of Knowledge, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane Library and Physiotherapy Evidence Database (PEDro)] identifying potential papers and screening for inclusion criteria by two independent reviewers; data extraction; and finally rating of internal validity and strength of the evidence, using a published valid and reliable scale. Meta-analysis estimated pooled point prevalence rates using a random effects model. In total, 17 studies involving 2529 patients were included in the review. Overall point prevalence rates for NP were established at 53% (38.58-67.47); 19% (13.26-26.39) for at-level NP and 27% (19.89-34.61) for below-level NP, with high heterogeneity noted (I 2 = 84-93%). Prevalence rates for NP following SCI are high. Future studies should include established definitions, classification systems and assessment tools for NP at defined time points post SCI to follow the trajectory of this problem across the lifespan and include indices of sleep, mood and interference to allow for appropriate, optimal and timely NP management for each patient. What does this review add?: This is the first systematic review and meta-analysis to record pooled point prevalence of neuropathic pain post spinal cord injury at 53%. Additional pooled analysis shows that neuropathic pain is more common below the level of lesion, in patients with tetraplegia, older patients and at 1 year post injury.
Introduction
Chronic pain is a common secondary complications post spinal cord injury (SCI), with estimated prevalence of 61% reported (van Gorp et al., 2015) . Pain can have an all-encompassing, detrimental effect, resulting in reduced quality of life (Westgren and Levi, 1998; Vall et al., 2006) , depression (Kishi et al., 1995; Cairns et al., 1996) and sleep disturbances (Budh et al., 2005) .
Neuropathic pain (NP) presents at or below the level of injury (Bryce et al., 2012) and is cited as the most 'severe pain' post SCI . It is largely refractory to current treatment approaches dominated by pharmacotherapy, of which pregabalin has shown the most effectiveness from randomized controlled trials (Siddall et al., 2006; Cardenas et al., 2013) . Patients frequently experiment with nonpharmacological treatments (Budh and Lundeberg, 2004 ); yet, to date, there is a significant lack of research for behavioural and physical approaches for SCI NP (Mehta et al., 2013) .
Neuropathic pain post SCI is associated with statistically significant increases in the utilization of health care resources. When compared to individuals with SCIs who do not have NP, visits to physicians, emergency departments, required surgical procedures and prescription utilization for NP incur an incremental cost implication of $17,369 per annum per patient (Margolis et al., 2014) .
A lack of clarity exists in the literature regarding the profile of NP post SCI. Two published systematic reviews previously reported the prevalence of general chronic pain post injury (Dijkers et al., 2009; van Gorp et al., 2015) . One review included traumatic SCIs only (Dijkers et al., 2009 ) and the second one excluded studies reporting NP (van Gorp et al., 2015) . A published review of determinants and chronicity of NP post SCI reported NP prevalence at 40% (Margot-Duclot et al., 2009) . Limitations of that review included that NP did not require a definition or classification and it failed to employ statistical meta-analysis.
To date, the presentation of NP in relation to SCI or demographic characteristics remains undefined. Some studies report that NP is more prevalent in paraplegia (Davidoff et al., 1987; Vall et al., 2011) , incomplete lesions and traumatic SCIs (Davidoff et al., 1987; Vall et al., 2011; Teixeira et al., 2013) , in women (Budh et al., 2003) and in older patients (Anke et al., 1995; Stormer et al., 1997) , but others report contradictory findings (Werhagen et al., 2004; Margot-Duclot et al., 2009; Nakipoglu-Yuzer et al., 2013; Finnerup et al., 2014) . To date, no review has proposed metaanalysis of NP prevalence in the SCI sub-populations, an area where conflict in the literature exists. Furthermore, reports indicate that NP either intensifies (Siddall, 2009) or remains at stable levels post injury (Margot-Duclot et al., 2009; Finnerup and Baastrup, 2012; D'Angelo et al., 2013; Felix, 2014) .
This study aims to systematically review the literature addressing NP from studies which include an adequate definition and assessment of NP post SCI. Where possible meta-analysis will be undertaken to estimate pooled point prevalence rates of NP in the total population, in sub-groups of the population defined by SCI and demographic characteristics and at specific time points post injury.
Methods

Study selection
As no established guideline for systematic reviews of prevalence studies exists, the conduct and reporting of this review was informed by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Moher et al., 2009 ) where applicable.
Phase 1 database search
Guided by a medical liaison librarian, an inclusive search strategy was developed to identify studies reporting the prevalence of NP following SCI (Supporting Information Table S1 ). Medical Subject Headings (MESH) or Controlled Vocabulary, appropriate to each database, in addition to free text were employed. Limits of human studies and English language were applied where databases were allowed.
Two search strings included a variety of terms used to describe SCI and NP, the singular and plural of each American and English spelling versions combined using the Boolean operator OR. Each search string (SCI and NP) was combined with the Boolean operator AND. No restrictions in study designs were applied in the initial search.
Six electronic databases were searched from inception up to March 31st 2015: PubMed, Embase, Web of Knowledge, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Cochrane Library and Physiotherapy Evidence Database (PEDro). To identify additional studies, references from reviews and included articles were cross-checked.
Inclusion and exclusion criteria
Studies comprising individuals ≥18 years of age with traumatic or non-traumatic SCI, where NP prevalence was reported, were included. To ensure accuracy in NP reports within studies, each study was required to provide evidence of either (1) a definition of NP (an IASP definition or a definition that closely mapped to same) or (2) reference for a classification system for NP after SCI [the international spinal cord injury pain (ISCIP) consensus on classification of pain after SCI (Bryce et al., 2012) or a classification system that closely mapped to same, and included a number of ISCIP descriptors such as: 'hotburning', 'tingling', 'pricking', 'pins and needles', 'sharp', 'shooting', 'squeezing', 'painful cold' and 'electric shock-like'] . Studies were analysed for inclusion by the two independent reviewers (D.B., O.L.) based on the criteria outlined. Where disagreement arose regarding the definition or classification of NP cited, studies were discussed with a third party (B.M.F.) and a resolution was reached.
Exclusion criteria included studies, where all subjects were selected on the basis of reported pain; intervention studies, where the recruited sample was not representative of the SCI population as a whole; review articles (after references were cross-checked) and conference abstracts.
Phase 2 data extraction
Results from all search engines were imported to EndNote desktop (version 7.2) and the duplicates were removed. Results were screened by title by one reviewer (D.B) and after irrelevant studies were excluded, studies were independently screened by abstract by two reviewers (D.B., O.L.). Remaining citations (n = 69) were obtained in full-text format and again were independently double-reviewed against inclusion criteria (D.B., O.L.). Reasons for exclusion of studies were recorded (Supporting Information Table S2 ). Where disagreement arose, studies were discussed with a third party (B.M.F.) and a resolution was reached (n = 11).
Information from included studies was summarized in tabular format under the following headings: study design, sample size, response rate, sample selection methodology, inclusion criteria, study population characteristics, time points from SCI to assessments, definition of NP employed, assessment tool used to identify NP, recall periods for NP report, NP prevalence including at and below-level NP and overall NP and descriptions of non-responders.
Phase 3 quality assessment
The quality of studies was assessed independently by two reviewers (D.B., O.L.) based on established criteria recommended by Leboeuf-Yde and Lauritsen (1995) and Walker (2000) . The original recommendations were created for low back pain prevalence studies and altered specifically for SCI (van Gorp et al., 2015) . Each study was scored from a maximum of 18 points. Fulfilment of 75% of criteria is indicative of a good quality study (Leboeuf-Yde and Lauritsen, 1995; Walker, 2000) . Any discrepancy in scoring was discussed with a third party (B.M.F.) and consensus reached.
Meta-analysis
Proposed meta-analysis included pooled point prevalence of NP, including at and below-level NP and at defined time points post SCI using R software (version 3.1.3) (R Core Team, 2015) .
Proposed sub-analysis, where data permitted, included pooled point prevalence of NP in tetraplegia versus paraplegia, complete versus incomplete SCI, traumatic versus non-traumatic SCIs, in men versus women, in older versus younger patients and at different timelines post injury. Acute, subacute and intermediate phase of SCI were collapsed into one variable and defined as acute SCI, this included any study providing data up to 6 months post SCI, remaining studies which recorded NP at greater than 6 months post SCI were defined as chronic SCI (Rowland et al., 2008) . A random effects model was proposed for subanalysis due to the expected heterogeneity across studies (Higgins and Green, 2011) . Where data were presented on the same population at different time points in two or more manuscripts, to avoid duplication of data, the largest group available was taken for inclusion in the overall analysis. Where group sizes were unchanged across assessments, the most recent assessment was used in the overall analysis. The number of cases of NP and total sample size were entered for individual studies and pooled point prevalence was calculated and displayed in forest plots.
Results
From an initial total of 3075 studies, 17 studies were included in the review; eight prospective studies (New et al., 1997; Siddall et al., 1999 Siddall et al., , 2003 Aito et al., 2007; Zeilig et al., 2012; Adriaansen et al., 2013; Wen et al., 2013; Finnerup et al., 2014) , six cross-sectional studies (Frisbie and Aguilera, 1990; Levi et al., 1995; Barrett et al., 2003; Budh et al., 2003; Heutink et al., 2011; Celik et al., 2013) , and three retrospective studies (Werhagen et al., 2004 (Werhagen et al., , 2012 . A PRISMA flow diagram (Moher et al., 2009 ) of the selection process is summarized in Supporting Information Figure S1 .
Characteristics of studies
Supporting Information Table S3 summarizes the characteristics of included studies. A total of 2529 individuals with SCIs were analysed, with study sizes ranging from 24 to 456 participants. Between 44% (Wen et al., 2013) and 92% (New et al., 1997) of respondents were men. Overall participants' age ranged from 31 (Celik et al., 2013) to 56 years (Werhagen et al., 2012) . Ten studies (Frisbie and Aguilera, 1990; Levi et al., 1995; Siddall et al., 1999 Siddall et al., , 2003 Werhagen et al., 2004 Werhagen et al., , 2012 Aito et al., 2007; Celik et al., 2013; Wen et al., 2013; Finnerup et al., 2014) included only patients with traumatic SCIs. One study focussed solely on non-traumatic SCIs . The remaining six studies included both, with traumatic SCIs frequency ranging from 64% (Heutink et al., 2011) to 84% (Barrett et al., 2003) .
Ten studies were conducted in European countries (Levi et al., 1995; Budh et al., 2003; Werhagen et al., 2004 Werhagen et al., , 2007 Werhagen et al., , 2012 Aito et al., 2007; Heutink et al., 2011; Adriaansen et al., 2013; Celik et al., 2013; Finnerup et al., 2014) , four in Australia (New et al., 1997; Siddall et al., 1999 Siddall et al., , 2003 Barrett et al., 2003; Zeilig et al., 2012) and the remainders were based in the United States (Frisbie and Aguilera, 1990) , Israel (Zeilig et al., 2012) and China (Wen et al., 2013) .
Response rates, defined in studies as the number of subjects who participated from those invited, and in surveys as those who responded from those who were contacted, were 90% or higher in seven studies (Frisbie and Aguilera, 1990; Levi et al., 1995; New et al., 1997; Siddall et al., 1999; Budh et al., 2003; Aito et al., 2007; Zeilig et al., 2012) , above 70% in four studies (Barrett et al., 2003; Siddall et al., 2003; Werhagen et al., 2012; Wen et al., 2013) , below 70% in three studies (Heutink et al., 2011; Adriaansen et al., 2013; Finnerup et al., 2014) , not disclosed in one study (Celik et al., 2013) and not applicable in two retrospective studies (Werhagen et al., 2004 . Only two studies (Wen et al., 2013; Finnerup et al., 2014) used validated NP screening tools for assessment.
Data from three manuscripts (Levi et al., 1995; Budh et al., 2003; Siddall et al., 2003) were excluded from meta-analysis, as the patient cohort was reported in other papers (Siddall et al., 1999; Werhagen et al., 2004 ) included in the current review. In one study (Werhagen et al., 2012) , data from two different countries were reported. Here, only the Swedish cohort was excluded due to overlap with another study (Werhagen et al., 2004) . Authors from five studies (New et al., 1997; Demirel et al., 1998; Aito et al., 2007; Celik et al., 2013; Finnerup et al., 2014) , where data were displayed in figures and bar-charts, were contacted for exact numeric data. Four authors responded (New et al., 1997; Aito et al., 2007; Celik et al., 2013; Finnerup et al., 2014) and provided study results; the fifth was excluded when no response to correspondence was received (Demirel et al., 1998) .
Quality assessment
Quality assessment of each included study is summarized in Supporting Information Table S4 . The overall mean quality score achieved 14.5 AE 2.7 was above the minimum threshold score of 13.5 for a good quality study classification (Leboeuf-Yde and Lauritsen, 1995; Walker, 2000) . Four studies (Frisbie and Aguilera, 1990; Heutink et al., 2011; Zeilig et al., 2012; Celik et al., 2013) were classified as poorer quality (<13.5). Where feasible, in the planned meta-analyses, these studies were removed in subsequent sensitivity analysis. Table 1 outlines assessment methods and NP prevalence rates in each study. The presence of NP was examined from within 2 weeks (Siddall et al., 1999; Zeilig et al., 2012) to 25 years or more (Werhagen et al., 2012) post SCI. Prevalence rates were recorded using a range of methodologies: over the phone, n = 2 Wen et al., 2013) ; a self-reported questionnaire, n = 1 (Adriaansen et al., 2013) ; a postal survey, n = 1 (Heutink et al., 2011) ; examination by a neurologist, n = 5 (Frisbie and Aguilera, 1990; Levi et al., 1995; New et al., 1997; Aito et al., 2007; Werhagen et al., 2012) ; a standardized pain interview, n = 3 (Barrett et al., 2003; Budh et al., 2003; Celik et al., 2013) and sensory testing and pain interview, n = 5 (Siddall et al., 1999; Werhagen et al., 2004 Werhagen et al., , 2007 Zeilig et al., 2012; Finnerup et al., 2014) .
Assessment of neuropathic pain
Four studies defined NP according to the IASP definition of NP, two studies (Siddall et al., 1999 cited the older definition (Merskey and Bogduk 1994) and the remaining two studies (Wen et al., 2013; Finnerup et al., 2014) used the updated version (Treede et al., 2008) . Nine studies used classification systems for SCI pain, where two studies were guided by the ISCIP classification (Wen et al., 2013; Finnerup et al., 2014) , seven studies (Siddall et al., 1999 Barrett et al., 2003; Werhagen et al., 2004 Werhagen et al., , 2007 Werhagen et al., , 2012 Celik et al., 2013) quoted the classification devised by Siddall et al. (1997 Siddall et al. ( , 2000 (Siddall et al., 1997 (Siddall et al., , 2000 and one study (Adriaansen et al., 2013) cited work from Burchiel and Hsu (2001) (Burchiel and Hsu, 2001) . The remaining studies quoted other literature (New et al., 1997; Budh et al., 2003; Heutink et al., 2011; Zeilig et al., 2012) or used a self-developed definition and classification of NP (Frisbie and Aguilera, 1990; Levi et al., 1995; Aito et al., 2007) , which were deemed to be suitable for inclusion by the two independent reviewers (D.B, O.L). 
Neuropathic pain prevalence
A number of meta-analyses were undertaken to determine NP pooled prevalence rates. Overall point prevalence rates of NP for all studies and for acute and chronic SCI were determined. Point prevalence of NP at-and below-level for all studies and for acute and chronic SCI was determined. Furthermore, sub-analysis of NP prevalence in paraplegia versus tetraplegia presentations in traumatic SCIs, in older patients versus younger patients and at 1 year post SCI was conducted.
Overall neuropathic pain point prevalence
From a total of 12 studies with 1401 patients, pooled prevalence for NP was 53% (95% CI = 43.33-63.38, I 2 = 91%) (Supporting Information Figure S2 ). Sensitivity analysis, where low quality studies were removed, resulted in no reduction in pooled prevalence 53% (95% CI = 38.58-67.47) established from a total of 938 patients ( Fig. 1 ). High heterogeneity, I 2 = 93% remained. Insufficient data (n = 2 studies) were presented to allow calculation of an overall NP pooled prevalence rate, where strict IASP definition of NP was reported. Prevalence rates in the two studies fulfilling this criterion ranged from 34% to 74%.
Overall NP point prevalence in acute SCI
From a total of three studies with 142 subjects, pooled prevalence was 52% (95% CI = 34.38-69.27, I 2 = 73%) (Fig. 2) . Further sensitivity analysis was not possible due to the lower number of included studies.
Overall NP point prevalence in chronic SCI
From a total of nine studies with 1259 subjects, pooled prevalence was 55% (95% CI = 42.35-66.42, I 2 = 93%) (Supporting Information Figure S2 ) increasing to 56% (95% CI = 37.11-73.47, I 2 = 95%) during sensitivity analysis (Fig. 3) . After 1 year post injury from a total of seven studies with 1013 subjects, pooled prevalence was 44% (95% CI = 36.82-51.66, I 2 = 78%) (Supporting Information Figure S2 ) decreasing to 43% (95% CI = 34.79-51.55, I 2 = 69%) during sensitivity analysis (Supporting Information Figure S2 ).
NP point prevalence at-level
From a total of nine studies with 1141 subjects, overall pooled at-level NP prevalence was 19% (95% CI = 13.26-26.39, I 2 = 84.5%) (Supporting Information Figure S2) . From a total of three studies in acute SCI of 188 subjects, pooled at-level prevalence was 27% (95% CI = 15.93-41.12, I 2 = 70%) (Fig. 4) . Further sensitivity analysis was not possible due to the lower number of included studies. From a total of six studies in chronic SCI of 953 pooled atlevel prevalence was 16% (95% CI = 10.19-24.47, I 2 = 86%) (Supporting Information Figure S2 ) decreasing to 13% (95% CI = 10.80-15.95, I 2 = 0%) during sensitivity analysis (Fig. 5) . From a total of three studies with 183 subjects who adhered to strict IASP definition of NP, pooled at-level NP prevalence was 29% (95% CI = 19.65-40.85, I 2 = 55%) (Supporting Information Figure S2 ).
NP point prevalence below-level
From a total of nine studies with 1141 subjects, overall pooled below-level NP prevalence was 27%
Study
Random effects model
Heterogeneity: I 2 = 93%, 2 = 0.6614, p < 0.0001
Adriaansen (2013) Aito (2007) Finnerup (2013) New (1997) Wen (2013) Werhagen (2004) Werhagen (2007) Werhagen (2012 
Study
Random effects model
Heterogeneity: I 2 = 94.9%, 2 = 0.8578, p < 0.0001 Adriaansen (2013) Aito (2007) Wen (2013) Werhagen (2004) Werhagen (2007) Werhagen (2012 (95% CI = 19.89-34.61, I 2 = 84%) (Supporting Information Figure S2) . From a total of three studies in acute SCI of 188 subjects, pooled below-level prevalence was 20% (95% CI = 7.06-45.18, I 2 = 89%) (Fig. 6) . Further sensitivity analysis was not possible due to the low number of included studies. From a total of six studies in chronic SCI of 953 pooled below-level prevalence was 30% (95% CI = 22.83-37.68, I 2 = 80%) (Supporting Information Figure S2 ) decreasing to 27% (95% CI = 21.18-33.50, I 2 = 55%) during sensitivity analysis (Fig. 7) . From a total of three studies with 183 subjects who adhered to strict IASP definition of NP, pooled below-level NP prevalence was 21% (95% CI = 6.86-49.23, I 2 = 90%) (Supporting Information Figure S2 ).
3.4.5.1 NP prevalence in complete SCI versus incomplete SCI lesions. Insufficient data were presented to allow comparison in NP prevalence by completeness of injury.
3.4.5.2 NP prevalence in paraplegia and tetraplegia presentations. From a total of three studies with 366 subjects, pooled NP prevalence in paraplegia was 46% (95% CI = 30.32-62.78, I 2 = 87%) (Supporting Information Figure S2 ). From the same three studies with 221 subjects, pooled NP prevalence in tetraplegia was 52% (95% CI = 34.38-68.95, I 2 = 75%) (Supporting Information Figure S2 ). One study was of low quality (Celik et al., 2013) ; however, further sensitivity analysis was not possible due to the low number of included studies.
3.4.5.3 NP prevalence in traumatic and non-traumatic SCI. From a total of seven studies with 819 subjects with traumatic SCIs pooled NP point prevalence was 47% (95% CI = 36.94-56.37, I 2 = 83%) (Supporting Information Figure S2 ) decreasing to 43% (95% CI = 34.75-51.62, I 2 = 69%) on sensitivity analysis (Supporting Information Figure S2 ). Only one study exclusively included 95 participants with nontraumatic SCIs , it reported overall NP rates of 38%, with 15% reporting at-level NP and 23% with below-level NP. Neither pooled prevalence calculation nor comparison between groups in this population was possible.
3.4.5.4 Age-related NP prevalence post SCI. Three studies categorized NP by age, allowing pooled prevalence rates of NP to be dichotomised to <50 or ≥50 years of age in accordance with the categories reported.
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Heterogeneity: I 2 = 70.3%, 2 = 0.2221, p = 0.0347 Finnerup (2014) Siddall ( For those <50 years of age (n = 449), the overall pooled point prevalence was 38% (95% CI = 33.49-42.44) with low heterogeneity (I 2 = 0%) (Supporting Information Figure S2 ).Those aged 50 or older (n = 130) had a higher prevalence rate of 51% (95% CI = 35.93-65.18, I 2 = 65%) (Supporting Information Figure S2 ).
3.4.5.5 Gender-related NP prevalence post SCI. Insufficient data were presented to allow comparison in NP prevalence by gender.
3.4.5.6 Neuropathic pain prevalence at specific time points post SCI. Only three studies reported overall point prevalence rates at a common specific time point post SCI of 1 year. From 266 subjects, the point prevalence of NP was 76% (95% CI = 44.98-92.83, I 2 = 94%) (Supporting Information Figure S2 ) at this time.
Discussion
This is the first systematic review and meta-analysis to consider the pooled point prevalence of NP post SCI. Rates of NP were found to be higher at 53%, than the 40% rate previously reported (Finnerup and Jensen, 2004; Margot-Duclot et al., 2009) . Atlevel (19%) and below-level (27%) NP pooled point prevalence rates were estimated for the first time in this current review. Neuropathic pain appears to be more prevalent after 6 months of injury compared with acute SCI. At-level NP develops more commonly in the acute stage post SCI and below-level NP begins to increase after 1 year. It was beyond the scope of this current review to provide an overview of the trajectory of NP post injury. The literature synthesized only reported NP at one common time point of 1 year post injury, which had a high point prevalence of 74%. Neuropathic pain was found to present more frequently in participants with tetraplegia and older patients. Clinically these populations should be prioritized when screening for NP. This review serves to highlight NP as a common problem post SCI that warrants further attention and effective management strategies (Finnerup and Baastrup, 2012; Felix, 2014) .
Less strict pain definitions previously led to overestimation of general chronic pain in SCI (van Gorp et al., 2015) . In the current review, where strict IASP definitions of NP were employed, meta-analyses were possible for at-level and below-level NP 
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Heterogeneity: I 2 = 55.4%, 2 = 0.0664, p = 0.0618 Barrett (2003) Wen (2013) Werhagen (2004) Werhagen (2007) Werhagen ( Figure 7 Neuropathic pain point prevalence below-level in chronic spinal cord injury (>6 months) sensitivity analysis. (Siddall et al., 1999; Wen et al., 2013; Finnerup et al., 2014) . Less strict definitions when compared with IASP adherent studies were found to underestimate at-level (À10%) and overestimate (+6%) below-level NP, respectively. At-level and belowlevel NP pooled prevalence rates when summed (19% and 27%, respectively), do not equal the total NP prevalence rate (53%). Given that subjects may present with both pain types simultaneously, this may be suggestive of an overestimation of overall NP prevalence or may be due to not all studies providing a breakdown of at-and below-level NP. Furthermore, below-level NP could be underreported by the inclusion of subjects with cauda equina lesions in analysis, only two studies (Werhagen et al., 2012; Adriaansen et al., 2013 ) excluded this cohort from study participation and no study reported excluding patients with this level of SCI from analysis. From this current review, one cannot definitively conclude whether less strict pain definitions led to overestimation of prevalence rates of NP after SCI. A lack of consensus in research studies on the assessment of NP post SCI had previously been identified as an issue (Bryce et al., 2012) . The IASP Neuropathic Pain Special Interest Group (NeuPSIG) guidelines advise that screening questionnaires are appropriate to identify patients who may have NP, and a further clinical examination with sensory testing should form the basis of a NP diagnosis (Haanp€ a€ a et al., 2011). The majority of included studies in the current review did not adhere to these guidelines with only two studies using validated NP questionnaires (Wen et al., 2013; Finnerup et al., 2014) and only five studies (Siddall et al., 1999; Werhagen et al., 2004 Werhagen et al., , 2007 Zeilig et al., 2012; Finnerup et al., 2014) including physical examination and sensory testing. The Neuropathic Pain Special Interest Group (NeuPSIG) guidelines also state, however, that a definite diagnosis of NP is attained if the patient has a diagnostic test confirming a lesion of the somatosensory system and negative or positive sensory signs, within the innervation territory of the lesion. A probable diagnosis of NP is recorded if one of these criteria is satisfied. In studies included in this systematic review, a somatosensory lesion was confirmed by SCI diagnosis and positive descriptors of NP reported, thus confirming a NP presentation. To allow for standardization across future research in this area, studies should appropriately define NP using the IASP definition (Treede et al., 2008) , include the ISCIP classification of SCI NP (Bryce et al., 2012) and use a validated NP screening tool, followed by a clinical examination including sensory testing when indicated. The Douleur Neuropathique 4 (DN4) (Bouhassira et al., 2005) is an example of one such tool to record NP in SCI patients with proven, high diagnostic accuracy (Calmels et al., 2009; Hallstrom and Norrbrink, 2011) and includes the pre-requisite sensory testing.
In the current review, 59% of included studies (n = 10) addressed traumatic SCI solely and 6% (n = 1) looked at non-traumatic SCI only. This indicates a bias in NP research towards SCI of traumatic origin. Current demographic trends of an anticipated increase in cancer-related SCIs with an ageing population (Guilcher et al., 2009 ), a characteristic previously linked with increased NP prevalence (Stormer et al., 1997; Demirel et al., 1998) , suggest that nontraumatic SCI will become more prevalent in the near future. It has been reported that traumatic SCIs (Davidoff et al., 1987; Vall et al., 2011) have increased levels of reported NP. In the current review, the pooled prevalence of NP for traumatic SCI (N = 5) was lower than the overall NP rates at 43%. Only one study enabled the prevalence rate in non-traumatic SCI to be identified at the lower rate of 38% . Further studies in non-traumatic SCI are required to redress this imbalance in the literature and establish pooled NP prevalence in this population.
Similar to reports of musculoskeletal pain (Ahacic and K areholt, 2010) and NP (Torrance et al., 2006) in the general population, the current review supports an association between increased age and NP prevalence in SCI with 13% more NP prevalence noted in those over 50, when compared with their younger counterparts. However, other studies included in the review did not provide data by age, prohibited their inclusion in the meta-analysis. Conflicting results exist in these studies with one study reporting increased below-level NP in younger patients (Finnerup et al., 2014) and one study finding overall NP to be more common in older patients (Budh et al., 2003) . The finding that increasing age is associated with more NP may be indicative of either a direct age effect on NP, or may reflect an increased prevalence because of time post injury. In the absence of data relating to NP prevalence at discreet time periods post injury, this cannot be elucidated further here.
Potential mechanisms for NP development post SCI described in detail in the literature (Siddall, 2009; Finnerup and Baastrup, 2012; D'Angelo et al., 2013) are now considered briefly within the context of the current findings. Peripheral mechanisms suggest that at the site of spinal cord trauma, surrounding nerve cells can exhibit inflammatory and neurochemical changes leading to augmented responsiveness to peripheral stimulation or neuronal hyper excitability which may give rise to at-level NP. (Siddall, 2009; Gwak and Hulsebosch, 2011; Finnerup and Baastrup, 2012) . This is supported by the findings in this review that at-level NP was more common in acute SCI. In addition to neuronal hyper excitability, activation of residual spinothalamic pathways (Siddall et al., 1999; Finnerup and Baastrup, 2012; D'Angelo et al., 2013) by inflamed damaged axons in the tract (Wasner et al., 2008 ), may cause below-level NP. This process has a longer time of onset explaining why below-level NP develops later within the first year post injury which was also upheld by findings of this review. Due to insufficient data presented it could not be determined whether at-or below-level NP was more common in incomplete or complete lesions, further research warranted the conflicting findings reported in the literature to date Werhagen et al., 2004; Finnerup et al., 2014) .
Finally, the results of this current review must be considered with the following limitations. Only studies in English were included and the high heterogeneity noted in much of the pooled analyses must be considered in the overall interpretation of the results. Standardization across future studies with respect to definition and classification of neuropathic pain is required.
In conclusion, this is the first systematic review and meta-analysis to provide pooled prevalence rates of NP post SCI. Prevalence rates for NP of over 50% post SCI highlight the significance of this problem, which is largely refractory to current treatment approaches and has a poor prognosis for recovery. Neuropathic pain is found to be more prevalent 1 year post injury, below lesion level, in older people and tetraplegics. While identified economic costs of this issue are measurable, the emotional and physical suffering for the individual is never fully captured. Future studies should include established definitions, classification systems and assessment tools for NP at clear time points post SCI to follow the trajectory of this problem across the lifespan and include indices of sleep, mood and interference to allow for appropriate, optimal and timely pain management for each patient.
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